* Expands ResMed's sleep management software solution, will help sleep labs
and physicians more efficiently guide patients into and through diagnosis to

    long-term treatment
  * Diagnostic management platform is upstream of and complementary to ResMed's
    current post-testing AirView and Brightree offerings
  * Somnoware platform will remain an open platform to enable sleep labs,
    pulmonary function testing facilities, and physicians to view results from

various testing solutions and help diagnosed patients get onto the treatment they need faster
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today
announced the acquisition of privately held Somnoware, a U.S. leader in sleep
and respiratory care diagnostics software.
Somnoware software streamlines the processes of physicians as well as sleep and
pulmonary function testing labs for diagnosing and evaluating a patient's sleep
and respiratory care test results, ordering PAP treatment equipment, setting up
appointments, tracking PAP compliance, and electronically providing this
information directly into a patient's electronic health record - all from within
the Somnoware platform.
"We are thrilled to welcome the Somnoware team to ResMed," said ResMed Sleep &
Respiratory Care President Lucile Blaise. "We're committed to driving wider
adoption of Somnoware's open and interoperable platform to help more people with
OSA or COPD get the diagnoses and treatment solutions they need. Improving
patients' experience and health outcomes is our common goal."
"We are very excited about this acquisition," said ResMed North America General
Manager Bill Shoop. "Somnoware's offering has been well received in the
marketplace and it naturally complements our ecosystem of digital solutions
across the patient care pathway. Our team is excited to add Somnoware to our
portfolio of solutions to help physicians, sleep labs, and HMEs drive greater
efficiency and deliver better patient care."
"I'm thrilled to join forces with ResMed and embark on a shared mission of
guiding people toward better sleep and improved breathing. Our partnership will
open new avenues to help physicians with the critical task of chronic care
management," said Subath Kamalasan, Somnoware cofounder and CEO. "Together, we
are committed to driving innovation and delivering solutions that improve the
health of patients with sleep disorders and other chronic respiratory diseases."
ResMed intends to retain all Somnoware staff, integrate its offerings into the
ResMed brand and solution ecosystem, and maintain the open and device-agnostic
nature of Somnoware's offerings so end users can keep interoperating with
various testing solutions and place orders for treatment devices and accessories
from any supplier.
The transaction's financial terms are not material to ResMed's consolidated
financial results and were not disclosed. Somnoware engaged Ziegler, a national
boutique investment bank, as its financial advisor, and King & Spalding LLP as
its legal advisor. DLA Piper served as ResMed's legal advisor.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and
keep people out of the hospital, empowering them to live healthier, higher-
quality lives. Our digital health technologies and cloud-connected medical
devices transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software platforms support the
professionals and caregivers who help people stay healthy in the home or care
setting of their choice. By enabling better care, we improve quality of life,
reduce the impact of chronic disease, and lower costs for consumers and
healthcare systems in more than 140 countries. To learn more, visit ResMed.com
and follow @ResMed.

 For Media                              For Investors
 Kristin Deuber                         Amy Wakeham
 resmed@allisonpr.com                   investorrelations@resmed.com
 (mailto:resmed@allisonpr.com)          (mailto:investorrelations@resmed.com)

Rowena Kelley
news@resmed.com
(mailto:news@resmed.com)Â